Clinical Trials Using Selinexor

Clinical trials are research studies that involve people. The clinical trials on this list are studying Selinexor. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-15 of 15
  • Selinexor in Treating Younger Patients with Recurrent or Refractory Solid Tumors or High-Grade Gliomas

    This phase I trial studies the side effects and best dose of selinexor in treating younger patients with solid tumors or high-grade gliomas that have come back (recurred) or do not respond to treatment (refractory). Drugs used in chemotherapy, such as selinexor, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 22 locations

  • Selinexor in Advanced Liposarcoma

    This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 279 total patients will be randomized to study treatment (selinexor or placebo).
    Location: 21 locations

  • Selinexor and Backbone Treatments of Multiple Myeloma Patients

    This study will independently assess the efficacy and safety of six combination therapies for the treatment of patients with Relapsed / Refractory Multiple Myeloma (RR MM) and Newly Diagnosed Multiple Myeloma (NDMM). The combinations to be evaluated include: selinexor + pomalidomide + dexamethasone (SPd), selinexor + bortezomib + dexamethasone (SVd), selinexor + lenalidomide + dexamethasone (SRd), selinexor + pomalidomide + dexamethasone + bortezomib (SPVd), selinexor + daratumumab + dexamethasone (SDd), and selinexor + carfilzomib + dexamethasone (SKd). The abbreviations for combination treatments have been revised to use V (Velcade) for bortezomib, R (Revlimid) for lenalidomide, D (Darzalex) for daratumumab, and K (Kyprolis) for carfilzomib.
    Location: 6 locations

  • Selinexor with Multiple Standard Chemotherapy Regimens in Treating Patients with Advanced Malignancies

    This phase Ib trial studies the side effects and best dose of selinexor when given together with several different standard chemotherapy regimens in treating patients with malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Selinexor may stop the growth of cancer cells by blocking enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Studying selinexor with different standard chemotherapy regimens may help doctors learn the side effects and best dose of selinexor that can be given with different types of treatments in one study.
    Location: 5 locations

  • Selinexor, Carfilzomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma

    This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as selinexor and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving selinexor, carfilzomib, and dexamethasone may be a better treatment for multiple myeloma.
    Location: 5 locations

  • Selinexor and Docetaxel in Treating Participants with Stage IV KRAS Mutant Non-Small Cell Lung Cancer

    This phase I / II trial studies the safety and best dose of selinexor and docetaxel in treating participants with stage IV KRAS-mutation non-small cell lung cancer that has spread to other places in the body. Selinexor may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving selinexor and docetaxel may work better in treating participant with stage IV KRAS mutant non-small cell lung cancer.
    Location: 2 locations

  • Selinexor and Ibrutinib in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

    This phase I trial studies the side effects and best dose of selinexor when given together with ibrutinib in treating patients with chronic lymphocytic leukemia or aggressive non-Hodgkin lymphoma that has returned after a period of improvement or does not respond to treatment. Selinexor and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

    This phase Ib trial studies the side effects and best dose of venetoclax and selinexor and how well they work in treating patients with high risk hematologic malignancies such as diffuse large B-cell lymphoma, multiple myeloma, or acute myeloid leukemia that have come back (recurrent) or do not respond to treatment (refractory). Venetoclax functions by inhibiting or slowing down a protein in the body called bcl-2, which is involved in slowing down the normal process by which old cells in the body are cleared (called apoptosis). Selinexor functions by trapping “tumor suppressing proteins” within the cell and causing the cancer cells to die or stop growing. This study examines the effects, if any, of selinexor and venetoclax on high risk hematologic malignancies and on the body, including any side-effects.
    Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee

  • Selinexor and Ixazomib for the Treatment of Locally Advanced Unresectable or Metastatic Sarcoma

    This phase I trial studies the side effects and best dose of selinexor when given together with ixazomib in treating patients with sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection (locally advanced unresectable) or has spread to other places in the body (metastatic). Selinexor blocks the activity of a protein which transports certain molecules between different parts of a cell. Many cancers disrupt the normal location of proteins and other molecules to allow the cancer to keep growing. Ixazomib is proteasome inhibitor. Proteasomes are responsible for breaking down certain proteins within the cell. Ixazomib allows some proteins and molecules to remain active for a longer time. Selinexor may work better in treating sarcoma when combined with ixazomib.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • Selinexor in Treating Patients with Myelofibrosis Intolerant or Resistant to JAK1 / 2 Inhibitors

    This phase II trial studies how well selinexor works in treating patients with myelofibrosis that does not respond to or is intolerant to JAK1 / 2 inhibitors. Drugs used in chemotherapy, such as selinexor, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah

  • Maintenance With Selinexor / Placebo After Combination Chemotherapy in Endometrial Cancer [SIENDO]

    Patients with primary stage IV or recurrent disease who are in partial or complete response after having completed a single line of at least 12 weeks of taxane-platinum combo therapy will be randomized to selinexor or placebo until disease progression.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Selinexor in Treating Participants with Advanced Thymic Epithelial Tumor

    This phase II trial studies how well selinexor works in treating participants with thymic epithelial tumor that has spread to other places in the body. Selinexor may stop the growth of tumor cells by blocking some of the proteins needed for cell growth.
    Location: 2 locations

  • Selinexor and Combination Chemotherapy in Treating Patients with Advanced B Cell Non-Hodgkin Lymphoma or Newly Diagnosed Diffuse Large B Cell Lymphoma

    This phase Ib / II trial studies the side effects and best dose of selinexor and how well it works when given together with combination chemotherapy in treating patients with B cell non-Hodgkin lymphoma that has spread to other places in the body or newly diagnosed diffuse large B cell lymphoma. Selinexor may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving selinexor and combination chemotherapy may work better in treating patients with B cell non-Hodgkin lymphoma or diffuse large B-cell lymphoma.
    Location: 2 locations

  • Cytarabine and Daunorubicin Hydrochloride with or without Selinexor in Treating Older Patients with Acute Myeloid Leukemia

    This randomized phase II trial studies how well cytarabine and daunorubicin hydrochloride with or without selinexor work in treating older patients with acute myeloid leukemia. Drugs used in chemotherapy, such as cytarabine and daunorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Selinexor may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving cytarabine and daunorubicin hydrochloride with selinexor may kill more cancer cells in older patients with acute myeloid leukemia.
    Location: Wake Forest University Health Sciences, Winston-Salem, North Carolina

  • Selinexor, High-Dose Melphalan, and Dexamethasone before Stem Cell Transplant in Treating Patients with Multiple Myeloma

    This phase I / II trial studies the side effects and best dose of selinexor and how well it works when given together with high-dose melphalan and dexamethasone before stem cell transplant in treating patients with multiple myeloma. Selinexor may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy, such as melphalan and dexamethasone, before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient’s bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving selinexor, high-dose melphalan, and dexamethasone before stem cell transplant may work better in treating patients with multiple myeloma.
    Location: Moffitt Cancer Center, Tampa, Florida